Study characterizes sex-stratified canine immune aging and responses to geroprotectors

A cross-sectional study of laboratory Beagles mapped non-linear, sex-stratified immune aging patterns and identified rapamycin as the most active cytokine-modulating intervention among evaluated geroprotectors.

Researchers published a study in Biogerontology characterizing the age-associated hematologic and serum cytokine profiles in a controlled cohort of 80 intact laboratory Beagles aged 1 to 11 years.

The study established that canine immune aging is heterogeneous and non-linear, with several absolute leukocyte counts declining with age before rising again in geriatric dogs.

Serum cytokine profiles exhibited distinct, sex-stratified patterns, showing more age-associated cytokine variations in males than in females, although formal age-by-sex interactions did not survive false discovery rate correction.

An exploratory 90-day intervention in 24 young Beagles comparing rapamycin, canagliflozin, and dietary restriction revealed that rapamycin was associated with the broadest endpoint cytokine response.

Canagliflozin demonstrated narrower cytokine differences alongside descriptive body-weight reduction, while dietary restriction reduced body weight without altering measured immune endpoints.

Canines are key translational models in geroscience due to shared environmental exposures and similar age-related physiological decline, making characterizations of their baseline immune aging highly valuable.

Identifying sex-stratified variations in immune baseline patterns highlights the necessity of sex-stratified designs in veterinary and translational human aging trials.

The comparative intervention data, though exploratory and limited by small group sizes and endpoint-only measurements, reinforces the distinct physiological profiles of rapamycin and canagliflozin in a large-animal model.

These findings provide baseline physiological and immunological mapping that can support the design of preclinical and veterinary translation studies for companies targeting immunosenescence.

The comparative activity of rapamycin in modulating cytokine profiles supports ongoing therapeutic interest in mTOR pathway inhibition for immune rejuvenation.

Future longitudinal studies to validate these cross-sectional immune patterns across the canine lifespan and larger-scale trials to confirm the clinical efficacy of short-term geroprotective interventions.